CBT Stock Analysis: Cabot | NYSE
Specialty Chemicals | NYSE, USA | Market Cap: 3.972m USD | 12M Return: 4.6% | US1270551013 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 31.7M
EPS Trend: 55.7%
Qual. Beats: 0
Rev. Trend: -83.9%
Qual. Beats: 1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Cabot Corporation (NYSE: CBT) is a U.S.-based specialty chemicals and performance materials producer founded in 1882 and headquartered in Boston, Massachusetts. The company operates through two segments: Reinforcement Materials, which supplies carbon black primarily used as a reinforcing agent in tires and industrial rubber products, and Performance Chemicals, which provides specialty carbons, fumed silica, fumed alumina, aerogel, and other advanced materials.
Cabots products serve a wide range of end-markets, including automotive tires, electric vehicle batteries, inks, coatings, adhesives, plastics, cosmetics, and pharmaceuticals. The company distributes through its own sales representatives and third-party distributors across the Americas, Europe, the Middle East, Africa, and Asia Pacific. Classified within the Materials sector as a Commodity Chemicals producer, Cabots Reinforcement Materials business is structurally tied to global tire demand, while its Performance Chemicals portfolio targets higher-growth applications such as lithium-ion battery components, EV conductive additives, and thermal insulation.
- Tire demand softness pressures reinforcement carbon black margins
- EV battery materials fuel Performance Chemicals segment growth
- Oil feedstock and energy costs squeeze specialty chemicals margins
| Net Income: 190.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -2.00 > 1.0 |
| NWC/Revenue: 14.58% < 20% (prev 21.83%; Δ -7.25% < -1%) |
| CFO/TA 0.13 > 3% & CFO 497.0m > Net Income 190.0m |
| Net Debt (1.11b) to EBITDA (690.0m): 1.61 < 3 |
| Current Ratio: 1.47 > 1.5 & < 3 |
| Outstanding Shares: last quarter (52.0m) vs 12m ago -3.35% < -2% |
| Gross Margin: 22.89% > 18% (prev 25.16%; Δ -2.27% > 0.5%) |
| Asset Turnover: 93.04% > 50% (prev 99.43%; Δ -6.39% > 0%) |
| Interest Coverage Ratio: 6.80 > 6 (EBIT TTM 510.0m / Interest Expense TTM 75.0m) |
| A: 0.13 (Total Current Assets 1.67b - Total Current Liabilities 1.14b) / Total Assets 3.98b |
| B: 0.46 (Retained Earnings 1.82b / Total Assets 3.98b) |
| C: 0.13 (EBIT TTM 510.0m / Avg Total Assets 3.91b) |
| D: 0.72 (Book Value of Equity 1.60b / Total Liabilities 2.24b) |
| Altman-Z'' = 4.00 = AA |
| DSRI: 1.11 (Receivables 731.0m/689.0m, Revenue 3.63b/3.81b) |
| GMI: 1.10 (GM 25.16% / 22.89%) |
| AQI: 0.93 (AQ_t 0.14 / AQ_t-1 0.15) |
| SGI: 0.95 (Revenue 3.63b / 3.81b) |
| TATA: -0.08 (NI 190.0m - CFO 497.0m) / TA 3.98b) |
| Beneish M = -2.93 (Cap -4..+1) = A |
As of October 07, 2026, the stock is trading at USD 77.11 with a total of 418,956 shares traded. Over the past week, the price has changed by -0.84%, over one month by -4.00%, over three months by -11.48% and over the past year by +4.63%.
Current recommended Stop Loss: 74.20 (which is 3.8% or 1.4 ATR below the current price).
Cabot has received a consensus analysts rating of 3.50. Therefore, it is recommended to hold CBT.
- StrongBuy: 2
- Buy: 0
- Hold: 3
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 91.3 | 18.4% |
P/E Trailing = 21.5546
P/E Forward = 9.9404
P/S = 1.0931
P/B = 2.495
P/EG = 1.0017
Revenue TTM = 3.63b USD
EBIT TTM = 510.0m USD
EBITDA TTM = 690.0m USD
Long Term Debt = 828.0m USD (from longTermDebt, last quarter)
Short Term Debt = 445.0m USD (from shortTermDebt, last quarter)
Debt = 1.36b USD (from shortLongTermDebtTotal, last quarter) + Leases 85.0m
Net Debt = 1.11b USD (calculated: Debt 1.36b - CCE 250.0m)
Enterprise Value = 5.08b USD (3.97b + Debt 1.36b - CCE 250.0m)
Interest Coverage Ratio = 6.80 (Ebit TTM 510.0m / Interest Expense TTM 75.0m)
EV/FCF = 18.08x (Enterprise Value 5.08b / FCF TTM 281.0m)
FCF Yield = 5.53% (FCF TTM 281.0m / Enterprise Value 5.08b)
FCF Margin = 7.73% (FCF TTM 281.0m / Revenue TTM 3.63b)
Net Margin = 5.23% (Net Income TTM 190.0m / Revenue TTM 3.63b)
Gross Margin = 22.89% ((Revenue TTM 3.63b - Cost of Revenue TTM 2.80b) / Revenue TTM)
Gross Margin QoQ = 18.74% (prev 24.00%)
Tobins Q-Ratio = 1.28 (Enterprise Value 5.08b / Total Assets 3.98b)
Interest Expense / Debt = 5.52% (Interest Expense 75.0m / Debt 1.36b)
Taxrate = 45.45% (190.0m / 418.0m)
NOPAT = 278.2m (EBIT 510.0m * (1 - 45.45%))
Current Ratio = 1.47 (Total Current Assets 1.67b / Total Current Liabilities 1.14b)
Debt / Equity = 0.85 (Debt 1.36b / totalStockholderEquity, last quarter 1.60b)
Debt / EBITDA = 1.61 (Net Debt 1.11b / EBITDA 690.0m)
Debt / FCF = 3.94 (Net Debt 1.11b / FCF TTM 281.0m)
Total Stockholder Equity = 1.57b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.86% (Net Income 190.0m / Total Assets 3.98b)
RoE = 12.07% (Net Income TTM 190.0m / Total Stockholder Equity 1.57b)
RoCE = 21.23% (EBIT 510.0m / Capital Employed (Equity 1.57b + L.T.Debt 828.0m))
RoIC = 8.96% (NOPAT 278.2m / Invested Capital 3.10b)
WACC = 7.03% (E(3.97b)/V(5.33b) * Re(8.41%) + D(1.36b)/V(5.33b) * Rd(5.52%) * (1-Tc(0.45)))
Discount Rate = 8.41% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -99.09 | Cagr: -3.01%
[DCF] Terminal Value 73.10% ; FCFF base≈307.8m ; Y1≈269.9m ; Y5≈218.1m
[DCF] Fair Price = 46.35 (EV 3.50b - Net Debt 1.11b = Equity 2.39b / Shares 51.6m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 55.71 | EPS CAGR: 6.11% | SUE: 0.13 | # QB: 0
Revenue Correlation: -83.92 | Revenue CAGR: -3.77% | SUE: 1.04 | # QB: 1
EPS current Quarter (2026-12-31): EPS=1.51 | Chg30d=-3.45% | Revisions=-25% | Analysts=2
EPS current Year (2026-09-30): EPS=6.36 | Chg30d=+0.45% | Revisions=+12% | GrowthEPS=-12.3% | GrowthRev=-0.8%
EPS next Year (2027-09-30): EPS=6.99 | Chg30d=-0.67% | Revisions=+12% | GrowthEPS=+9.8% | GrowthRev=+3.1%
[Analyst] Revisions Ratio: +7% (up=6, down=5)